复发性-话题@MedSci

#复发性#

452篇内容 | 2460人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1909899, encodeId=76001909899d7, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, objectType=article, longId=211980, objectId=f93f211980ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93f211980ae, replyNumber=0, likeNumber=117, createdTime=2022-04-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93f211980ae, moduleTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93f211980ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909874, encodeId=3f8d19098e471, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果, objectType=article, longId=207454, objectId=c0a120e454b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0a120e454b7, replyNumber=0, likeNumber=84, createdTime=2021-06-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0a120e454b7, moduleTitle=ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0a120e454b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909881, encodeId=70471909881f3, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, objectType=article, longId=207800, objectId=df3320e8001b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3320e8001b, replyNumber=0, likeNumber=74, createdTime=2021-12-30, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3320e8001b, moduleTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3320e8001b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909872, encodeId=8dbe19098e2ea, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=55, createdTime=2021-04-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909879, encodeId=baef19098e907, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, objectType=article, longId=207690, objectId=df0620e690db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0620e690db, replyNumber=0, likeNumber=77, createdTime=2021-11-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0620e690db, moduleTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df0620e690db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909928, encodeId=9877190992884, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：中心静脉导管相关性静脉血栓形成患儿复发性血栓事件的预防, objectType=article, longId=220043, objectId=08a52200438a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a52200438a, replyNumber=0, likeNumber=0, createdTime=2022-02-02, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a52200438a, moduleTitle=Blood：中心静脉导管相关性静脉血栓形成患儿复发性血栓事件的预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a52200438a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909890, encodeId=8a2519098904d, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者, objectType=article, longId=210738, objectId=429f210e38af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=429f210e38af, replyNumber=0, likeNumber=54, createdTime=2021-05-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=429f210e38af, moduleTitle=Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=429f210e38af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909867, encodeId=18ca190986eb7, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, objectType=article, longId=206110, objectId=c0bd206110aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0bd206110aa, replyNumber=0, likeNumber=105, createdTime=2021-08-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0bd206110aa, moduleTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0bd206110aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909880, encodeId=94211909880d5, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=57, createdTime=2021-03-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909916, encodeId=b507190991685, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=JAMA Neurology：复发性-缓解性多发性硬化症，那种治疗策略更好？, objectType=article, longId=216504, objectId=6af221650420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6af221650420, replyNumber=0, likeNumber=77, createdTime=2022-06-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6af221650420, moduleTitle=JAMA Neurology：复发性-缓解性多发性硬化症，那种治疗策略更好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6af221650420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909935, encodeId=7788190993584, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症, objectType=article, longId=220605, objectId=a14b22060538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a14b22060538, replyNumber=0, likeNumber=0, createdTime=2022-07-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a14b22060538, moduleTitle=Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a14b22060538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909864, encodeId=c8471909864b5, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Clin Gastroenterology H: 肝硬化患者复发性腹水与死亡率的关系, objectType=article, longId=205858, objectId=bffe2058582f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bffe2058582f, replyNumber=0, likeNumber=73, createdTime=2021-12-01, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bffe2058582f, moduleTitle=Clin Gastroenterology H: 肝硬化患者复发性腹水与死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bffe2058582f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909921, encodeId=d9f2190992160, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, objectType=article, longId=217177, objectId=f20e21e177df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f20e21e177df, replyNumber=0, likeNumber=83, createdTime=2021-11-11, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f20e21e177df, moduleTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f20e21e177df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909910, encodeId=f3d71909910ac, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=91, createdTime=2021-10-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909920, encodeId=b32e19099206b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, objectType=article, longId=217065, objectId=6c6c21e06592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c6c21e06592, replyNumber=0, likeNumber=70, createdTime=2022-04-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c6c21e06592, moduleTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c6c21e06592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909863, encodeId=f2171909863a5, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, objectType=article, longId=205851, objectId=3ac1205851bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ac1205851bd, replyNumber=0, likeNumber=64, createdTime=2021-07-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ac1205851bd, moduleTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ac1205851bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909931, encodeId=23ac1909931bb, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, objectType=article, longId=220308, objectId=35f022030877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35f022030877, replyNumber=0, likeNumber=63, createdTime=2022-01-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35f022030877, moduleTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35f022030877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909917, encodeId=e386190991e97, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, objectType=article, longId=216579, objectId=57b22165e959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b22165e959, replyNumber=0, likeNumber=84, createdTime=2021-09-07, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b22165e959, moduleTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b22165e959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909858, encodeId=59cd1909858d0, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Can J Gastroenterol Hepatol：粪便微生物群移植(FMT)与富含乳酸菌的FMT在治疗复发性艰难梭菌感染中肠道微生物群的改变, objectType=article, longId=204575, objectId=b5602045e568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5602045e568, replyNumber=0, likeNumber=71, createdTime=2021-05-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5602045e568, moduleTitle=Can J Gastroenterol Hepatol：粪便微生物群移植(FMT)与富含乳酸菌的FMT在治疗复发性艰难梭菌感染中肠道微生物群的改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5602045e568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909901, encodeId=7ffd19099015b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Neurology:复发性发病的多发性硬化患者，年龄比疾病持续时间对死亡率影响更大, objectType=article, longId=212798, objectId=cff8212e98d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cff8212e98d2, replyNumber=0, likeNumber=76, createdTime=2021-10-20, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cff8212e98d2, moduleTitle=Neurology:复发性发病的多发性硬化患者，年龄比疾病持续时间对死亡率影响更大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff8212e98d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

2022-04-10

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果

2021-06-23

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

2021-12-30

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-04-17

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后

2021-11-13

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：中心静脉导管相关性静脉血栓形成患儿复发性血栓事件的预防

2022-02-02

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者

2021-05-15

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效

2021-08-27

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-03-27

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

JAMA Neurology：复发性-缓解性多发性硬化症，那种治疗策略更好？

2022-06-14

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症

2022-07-06

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Clin Gastroenterology H: 肝硬化患者复发性腹水与死亡率的关系

2021-12-01

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效

2021-11-11

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-10-17

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后

2022-04-10

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效

2021-07-03

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL

2022-01-09

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性

2021-09-07

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Can J Gastroenterol Hepatol：粪便微生物群移植(FMT)与富含乳酸菌的FMT在治疗复发性艰难梭菌感染中肠道微生物群的改变

2021-05-21

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Neurology:复发性发病的多发性硬化患者，年龄比疾病持续时间对死亡率影响更大

2021-10-20

科室
- - 订阅+
  - 更多科室
工具
服务